慢性および/または亜急性皮膚エリテマトーデスの成人におけるアニフロルマブの有効性と安全性を調査する研究 (LAVENDER)
抗マラリア療法に抵抗性および/または不耐性の慢性および/または亜急性皮膚エリテマトーデスの成人を対象としたアニフロルマブの有効性と安全性を評価するための多施設共同、無作為化、二重盲検、プラセボ対照、第III相試験
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85028
- Research Site
-
-
California
-
Covina、California、アメリカ、91722
- Research Site
-
La Jolla、California、アメリカ、92037
- Research Site
-
Los Angeles、California、アメリカ、90045
- Research Site
-
Los Angeles、California、アメリカ、90089
- Research Site
-
Orange、California、アメリカ、92868
- Research Site
-
San Francisco、California、アメリカ、94143
- Research Site
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Research Site
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06519
- Research Site
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20037
- Research Site
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33309
- Research Site
-
Miami、Florida、アメリカ、33174
- Research Site
-
Plantation、Florida、アメリカ、33324
- Research Site
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- Research Site
-
Chicago、Illinois、アメリカ、60611
- Research Site
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Research Site
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Research Site
-
Boston、Massachusetts、アメリカ、02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- Research Site
-
Bloomfield Hills、Michigan、アメリカ、48302
- Research Site
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Research Site
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198-5885
- Research Site
-
-
New York
-
New York、New York、アメリカ、10028
- Research Site
-
Rochester、New York、アメリカ、14642
- Research Site
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28207
- Research Site
-
Statesville、North Carolina、アメリカ、28625
- Research Site
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Research Site
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Research Site
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Research Site
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Research Site
-
-
Texas
-
Dallas、Texas、アメリカ、75390-8843
- Research Site
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- Research Site
-
Roanoke、Virginia、アメリカ、24016
- Research Site
-
-
-
-
-
Ciudad de Buenos Aires、アルゼンチン、1221
- Research Site
-
Córdoba、アルゼンチン、5000
- Research Site
-
Córdoba、アルゼンチン、X5004BAL
- Research Site
-
Quilmes、アルゼンチン、1878
- Research Site
-
San Miguel、アルゼンチン、1663
- Research Site
-
-
-
-
-
Cambridge、イギリス、CB2 0QQ
- Research Site
-
Leeds、イギリス、LS2 9JT
- Research Site
-
London、イギリス、NW1 2PG
- Research Site
-
London、イギリス、SE5 9RS
- Research Site
-
London、イギリス、SE1 7EH
- Research Site
-
London、イギリス、NW3 2QG
- Research Site
-
Newcastle upon Tyne、イギリス、NE1 4LP
- Research Site
-
-
-
-
-
Brescia、イタリア、25123
- Research Site
-
Cona、イタリア、44124
- Research Site
-
Florence、イタリア、50121
- Research Site
-
Milan、イタリア、20132
- Research Site
-
Naples、イタリア、80138
- Research Site
-
Reggio Emilia、イタリア、42123
- Research Site
-
Roma、イタリア、00144
- Research Site
-
Rome、イタリア、00168
- Research Site
-
-
-
-
-
Breda、オランダ、4818 CK
- Research Site
-
Rotterdam、オランダ、3015 GD
- Research Site
-
-
-
-
-
Kogarah、オーストラリア、3168
- Research Site
-
Melbourne、オーストラリア、3004
- Research Site
-
Mitcham、オーストラリア、3132
- Research Site
-
Westmead、オーストラリア、2145
- Research Site
-
Woolloongabba、オーストラリア、04102
- Research Site
-
-
-
-
-
Graz、オーストリア、8036
- Research Site
-
Innsbruck、オーストリア、6020
- Research Site
-
Linz、オーストリア、4020
- Research Site
-
Vienna、オーストリア、1130
- Research Site
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 3Z5
- Research Site
-
Toronto、Ontario、カナダ、M5T 2S8
- Research Site
-
-
-
-
-
Athens、ギリシャ、12462
- Research Site
-
Athens、ギリシャ、16121
- Research Site
-
-
-
-
-
Barranquilla、コロンビア、080020
- Research Site
-
Bogotá、コロンビア、110221
- Research Site
-
-
-
-
-
Barcelona、スペイン、8035
- Research Site
-
Barcelona、スペイン、08025
- Research Site
-
Castellon、スペイン、12004
- Research Site
-
Granada、スペイン、18012
- Research Site
-
L'Hospitalet de Llobregat、スペイン、08907
- Research Site
-
Las Palmas de Gran Canaria、スペイン、35010
- Research Site
-
Madrid、スペイン、28034
- Research Site
-
Madrid、スペイン、28041
- Research Site
-
Madrid、スペイン、28040
- Research Site
-
Madrid、スペイン、28006
- Research Site
-
Majadahonda、スペイン、28222
- Research Site
-
Salamanca、スペイン、37007
- Research Site
-
Seville、スペイン、41014
- Research Site
-
Valencia、スペイン、46014
- Research Site
-
Valencia、スペイン、46017
- Research Site
-
Vigo、スペイン、36200
- Research Site
-
-
-
-
-
Košice、スロバキア、04001
- Research Site
-
Piešťany、スロバキア、92101
- Research Site
-
-
-
-
-
Belgrade、セルビア、11000
- Research Site
-
Kragujevac、セルビア、34000
- Research Site
-
-
-
-
-
Bangkok、タイ、10330
- Research Site
-
Bangkok、タイ、10700
- Research Site
-
Hat Yai、タイ、90110
- Research Site
-
Khlong Luang、タイ、12120
- Research Site
-
Khon Kaen、タイ、40002
- Research Site
-
-
-
-
-
Osorno、チリ、200025
- Research Site
-
Santiago、チリ、7500571
- Research Site
-
Santiago、チリ、130021
- Research Site
-
-
-
-
-
Aarhus、デンマーク、641-8510
- Research Site
-
Copenhagen、デンマーク、2100
- Research Site
-
-
-
-
-
Cordaleo、トルコ(Türkiye)、35575
- Research Site
-
Istanbul、トルコ(Türkiye)、34098
- Research Site
-
Kayseri、トルコ(Türkiye)、38039
- Research Site
-
Samsun、トルコ(Türkiye)、55270
- Research Site
-
-
-
-
-
Berlin、ドイツ、10117
- Research Site
-
Bochum、ドイツ、44791
- Research Site
-
Dresden、ドイツ、01307
- Research Site
-
Erlangen、ドイツ、91054
- Research Site
-
Essen、ドイツ、45147
- Research Site
-
Freiburg im Breisgau、ドイツ、79104
- Research Site
-
Hanover、ドイツ、30625
- Research Site
-
Kiel、ドイツ、24105
- Research Site
-
Leipzig、ドイツ、04103
- Research Site
-
Mainz、ドイツ、55131
- Research Site
-
Marburg、ドイツ、35043
- Research Site
-
Regensburg、ドイツ、93053
- Research Site
-
Wuppertal、ドイツ、42283
- Research Site
-
-
-
-
-
Papatoetoe、ニュージーランド、2025
- Research Site
-
-
-
-
-
Iloilo City、フィリピン、5000
- Research Site
-
Lipa、フィリピン、4217
- Research Site
-
Manila、フィリピン、1000
- Research Site
-
-
-
-
-
Bois-Guillaume、フランス、76031
- Research Site
-
Dijon、フランス、21000
- Research Site
-
Lyon、フランス、69437
- Research Site
-
Montivilliers、フランス、76290
- Research Site
-
Nantes、フランス、44000
- Research Site
-
Paris、フランス、75010
- Research Site
-
Paris、フランス、75014
- Research Site
-
Paris、フランス、75013
- Research Site
-
Paris、フランス、75970
- Research Site
-
Poitiers、フランス、86000, FR
- Research Site
-
Toulouse、フランス、31059
- Research Site
-
-
-
-
-
Belo Horizonte、ブラジル、30150-221
- Research Site
-
Porto Alegre、ブラジル、90035903
- Research Site
-
Rio de Janeiro、ブラジル、22470-220
- Research Site
-
Salvador、ブラジル、40150-150
- Research Site
-
São Paulo、ブラジル、05403-000
- Research Site
-
-
-
-
-
Sofia、ブルガリア、1784
- Research Site
-
Sofia、ブルガリア、1463
- Research Site
-
Sofia、ブルガリア、1528
- Research Site
-
-
-
-
-
Braga、ポルトガル、4710-243
- Research Site
-
Lisbon、ポルトガル、1649-035
- Research Site
-
Porto、ポルトガル、4099-001
- Research Site
-
-
-
-
-
Katowice、ポーランド、40-851
- Research Site
-
Kielce、ポーランド、25-316
- Research Site
-
Ossy、ポーランド、40-027
- Research Site
-
Rzeszów、ポーランド、35-055
- Research Site
-
Warsaw、ポーランド、02-637
- Research Site
-
-
-
-
-
Guadalajara、メキシコ、44340
- Research Site
-
Guadalajara、メキシコ、44610
- Research Site
-
Mexico City、メキシコ、07760
- Research Site
-
Veracruz、メキシコ、91910
- Research Site
-
-
-
-
-
Bucharest、ルーマニア、020125
- Research Site
-
Iași、ルーマニア、700291
- Research Site
-
-
-
-
-
Changchun、中国、130021
- Research Site
-
Changsha、中国、410011
- Research Site
-
Chengdu、中国、610021
- Research Site
-
Chongqing、中国、400016
- Research Site
-
Dongguan、中国、523059
- Research Site
-
Guangzhou、中国、510120
- Research Site
-
Heilongjiang、中国、150086
- Research Site
-
Jinan、中国、250022
- Research Site
-
Shanghai、中国、200025
- Research Site
-
Shanghai、中国、200443
- Research Site
-
Shenzhen、中国、518053
- Research Site
-
Shenzhen、中国、518020
- Research Site
-
Shenzhen、中国、518052
- Research Site
-
Zhuzhou、中国、412007
- Research Site
-
Ürümqi、中国、CN-830004
- Research Site
-
-
-
-
-
Cape Town、南アフリカ、7500
- Research Site
-
Johannesburg、南アフリカ、2193
- Research Site
-
-
-
-
-
Kaohsiung City、台湾、83301
- Research Site
-
Taichung、台湾、404
- Research Site
-
Taipei、台湾、10449
- Research Site
-
-
-
-
-
Chūōku、日本、104-8560
- Research Site
-
Fukuoka、日本、812-8582
- Research Site
-
Kanazawa、日本、920-8641
- Research Site
-
Kita-gun、日本、761-0793
- Research Site
-
Nagoya、日本、457-8510
- Research Site
-
Nagoya、日本、467-8602
- Research Site
-
Wakayama、日本、641-8510
- Research Site
-
Yokohama、日本、232-0024
- Research Site
-
tabashi City、日本、173-8606
- Research Site
-
-
-
-
-
Seoul、韓国、03080
- Research Site
-
Seoul、韓国、06591
- Research Site
-
Seoul、韓国、06973
- Research Site
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
プラセボコンパレーター:Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
時間枠:At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in total CLASI-A score
時間枠:At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
時間枠:At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
時間枠:At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
時間枠:At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
時間枠:Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
時間枠:Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
時間枠:Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
時間枠:Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
時間枠:At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
時間枠:At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
時間枠:At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
時間枠:At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
時間枠:At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
時間枠:From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
時間枠:From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with adverse events
時間枠:Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- D346BC00001
- 2021-003698-70 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 共有時間枠
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共有アクセス基準
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。